NCT03071094View on ClinicalTrials.gov

A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 27, 2017

Primary Completion Date

September 30, 2020

Study Completion Date

February 3, 2021

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
BIOLOGICAL

Pexastimogene Devacirepvec (Pexa Vec)

Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 10\^9 pfu at day 1 and weeks 2 and 4

DRUG

Nivolumab

Nivolumab will be administered intravenously every 2 weeks (from week 2)

Trial Locations (2)

Unknown

Site No 0102, Nancy

Site No 0101, Paris

Sponsors

Lead Sponsor

Transgene
All Listed Sponsors
lead

Transgene

INDUSTRY